Even as Novartis takes home a partial win in court tied to its key blockbuster Entresto, the Swiss drugmaker continues to ...

Novartis has joined forces with a group representing cardiovascular disease patients organisations to push for changes in how health systems handle the world's number one killer. The Invisible ...

Story continues below photo gallery. This round of layoffs was triggered in part by the upcoming patent expiration for Novartis’ Entresto, its heart condition medication, according to the company.

The transaction, which is subject to customary closing conditions, is fully in line with Novartis’ growth strategy and therapeutic area focus, leveraging the company’s strength and expertise in the ...

The MoU combines HMRI and the University of Newcastle's research expertise with Novartis' medical solutions leadership ... president Matt Zeller stated: “Cardiovascular disease is still the ...

The Swiss pharma giant – which has its U.S. headquarters in East Hanover – said it aims to encourage football fans to "proactively manage their health." ...